nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—CYP2B6—Thiotepa—urinary bladder cancer	0.107	0.208	CbGbCtD
Cyclophosphamide—ABCB1—Mitomycin—urinary bladder cancer	0.0725	0.14	CbGbCtD
Cyclophosphamide—CYP2A6—Fluorouracil—urinary bladder cancer	0.0535	0.104	CbGbCtD
Cyclophosphamide—CYP3A4—Thiotepa—urinary bladder cancer	0.0329	0.0638	CbGbCtD
Cyclophosphamide—CYP2B6—Cisplatin—urinary bladder cancer	0.0296	0.0573	CbGbCtD
Cyclophosphamide—CYP2C8—Fluorouracil—urinary bladder cancer	0.0264	0.0511	CbGbCtD
Cyclophosphamide—CYP3A5—Etoposide—urinary bladder cancer	0.0229	0.0443	CbGbCtD
Cyclophosphamide—CYP2C8—Etoposide—urinary bladder cancer	0.022	0.0426	CbGbCtD
Cyclophosphamide—ABCB1—Gemcitabine—urinary bladder cancer	0.0209	0.0404	CbGbCtD
Cyclophosphamide—CYP2B6—Doxorubicin—urinary bladder cancer	0.0198	0.0384	CbGbCtD
Cyclophosphamide—CYP2C9—Fluorouracil—urinary bladder cancer	0.0184	0.0356	CbGbCtD
Cyclophosphamide—CYP2C9—Cisplatin—urinary bladder cancer	0.0156	0.0303	CbGbCtD
Cyclophosphamide—ABCB1—Cisplatin—urinary bladder cancer	0.0152	0.0294	CbGbCtD
Cyclophosphamide—ABCB1—Etoposide—urinary bladder cancer	0.0149	0.0289	CbGbCtD
Cyclophosphamide—ABCB1—Doxorubicin—urinary bladder cancer	0.0102	0.0197	CbGbCtD
Cyclophosphamide—ABCB1—Methotrexate—urinary bladder cancer	0.00985	0.0191	CbGbCtD
Cyclophosphamide—CYP2D6—Doxorubicin—urinary bladder cancer	0.00958	0.0185	CbGbCtD
Cyclophosphamide—CYP3A4—Etoposide—urinary bladder cancer	0.00893	0.0173	CbGbCtD
Cyclophosphamide—CYP3A4—Doxorubicin—urinary bladder cancer	0.00609	0.0118	CbGbCtD
Cyclophosphamide—CYP2C19—urine—urinary bladder cancer	0.00252	0.126	CbGeAlD
Cyclophosphamide—CYP2C9—urine—urinary bladder cancer	0.00196	0.0975	CbGeAlD
Cyclophosphamide—CYP3A4—urine—urinary bladder cancer	0.00149	0.0744	CbGeAlD
Cyclophosphamide—CYP2D6—urine—urinary bladder cancer	0.00147	0.0732	CbGeAlD
Cyclophosphamide—CYP2A6—prostate gland—urinary bladder cancer	0.00141	0.0702	CbGeAlD
Cyclophosphamide—CYP2A6—seminal vesicle—urinary bladder cancer	0.00119	0.0594	CbGeAlD
Cyclophosphamide—CYP2C18—vagina—urinary bladder cancer	0.00105	0.0524	CbGeAlD
Cyclophosphamide—CYP3A5—prostate gland—urinary bladder cancer	0.000714	0.0356	CbGeAlD
Cyclophosphamide—CYP2A6—vagina—urinary bladder cancer	0.000696	0.0347	CbGeAlD
Cyclophosphamide—CYP2C8—renal system—urinary bladder cancer	0.000539	0.0269	CbGeAlD
Cyclophosphamide—CYP3A5—renal system—urinary bladder cancer	0.000487	0.0242	CbGeAlD
Cyclophosphamide—CYP2B6—renal system—urinary bladder cancer	0.000484	0.0241	CbGeAlD
Cyclophosphamide—CYP2C19—vagina—urinary bladder cancer	0.000447	0.0223	CbGeAlD
Cyclophosphamide—CYP2C8—female reproductive system—urinary bladder cancer	0.000432	0.0215	CbGeAlD
Cyclophosphamide—CYP2C8—vagina—urinary bladder cancer	0.000391	0.0195	CbGeAlD
Cyclophosphamide—CYP2B6—female reproductive system—urinary bladder cancer	0.000387	0.0193	CbGeAlD
Cyclophosphamide—CYP2C9—female reproductive system—urinary bladder cancer	0.000384	0.0191	CbGeAlD
Cyclophosphamide—ABCB1—prostate gland—urinary bladder cancer	0.000379	0.0189	CbGeAlD
Cyclophosphamide—CYP3A4—renal system—urinary bladder cancer	0.000365	0.0182	CbGeAlD
Cyclophosphamide—CYP2D6—renal system—urinary bladder cancer	0.000359	0.0179	CbGeAlD
Cyclophosphamide—CYP3A5—vagina—urinary bladder cancer	0.000353	0.0176	CbGeAlD
Cyclophosphamide—CYP2B6—vagina—urinary bladder cancer	0.00035	0.0175	CbGeAlD
Cyclophosphamide—ABCB1—seminal vesicle—urinary bladder cancer	0.000321	0.016	CbGeAlD
Cyclophosphamide—CYP3A4—female reproductive system—urinary bladder cancer	0.000293	0.0146	CbGeAlD
Cyclophosphamide—CYP2D6—female reproductive system—urinary bladder cancer	0.000288	0.0143	CbGeAlD
Cyclophosphamide—ABCB1—epithelium—urinary bladder cancer	0.000279	0.0139	CbGeAlD
Cyclophosphamide—ABCB1—renal system—urinary bladder cancer	0.000259	0.0129	CbGeAlD
Cyclophosphamide—ABCB1—urethra—urinary bladder cancer	0.000254	0.0127	CbGeAlD
Cyclophosphamide—ABCB1—female reproductive system—urinary bladder cancer	0.000207	0.0103	CbGeAlD
Cyclophosphamide—ABCB1—vagina—urinary bladder cancer	0.000187	0.00933	CbGeAlD
Cyclophosphamide—ABCB1—lymph node—urinary bladder cancer	0.000121	0.00603	CbGeAlD
Cyclophosphamide—Dizziness—Thiotepa—urinary bladder cancer	8.5e-05	0.000234	CcSEcCtD
Cyclophosphamide—Stomatitis—Methotrexate—urinary bladder cancer	8.45e-05	0.000232	CcSEcCtD
Cyclophosphamide—Urticaria—Fluorouracil—urinary bladder cancer	8.45e-05	0.000232	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Methotrexate—urinary bladder cancer	8.43e-05	0.000232	CcSEcCtD
Cyclophosphamide—Body temperature increased—Fluorouracil—urinary bladder cancer	8.4e-05	0.000231	CcSEcCtD
Cyclophosphamide—Sweating—Methotrexate—urinary bladder cancer	8.31e-05	0.000229	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Cisplatin—urinary bladder cancer	8.31e-05	0.000228	CcSEcCtD
Cyclophosphamide—Paraesthesia—Etoposide—urinary bladder cancer	8.29e-05	0.000228	CcSEcCtD
Cyclophosphamide—Weight increased—Epirubicin—urinary bladder cancer	8.28e-05	0.000228	CcSEcCtD
Cyclophosphamide—Haematuria—Methotrexate—urinary bladder cancer	8.27e-05	0.000227	CcSEcCtD
Cyclophosphamide—Dyspnoea—Etoposide—urinary bladder cancer	8.23e-05	0.000226	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Epirubicin—urinary bladder cancer	8.21e-05	0.000226	CcSEcCtD
Cyclophosphamide—Vomiting—Thiotepa—urinary bladder cancer	8.17e-05	0.000225	CcSEcCtD
Cyclophosphamide—Pneumonia—Epirubicin—urinary bladder cancer	8.16e-05	0.000224	CcSEcCtD
Cyclophosphamide—Rash—Thiotepa—urinary bladder cancer	8.1e-05	0.000223	CcSEcCtD
Cyclophosphamide—Dermatitis—Thiotepa—urinary bladder cancer	8.1e-05	0.000223	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Methotrexate—urinary bladder cancer	8.09e-05	0.000222	CcSEcCtD
Cyclophosphamide—Headache—Thiotepa—urinary bladder cancer	8.05e-05	0.000221	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	8.05e-05	0.000221	CcSEcCtD
Cyclophosphamide—Decreased appetite—Etoposide—urinary bladder cancer	8.03e-05	0.000221	CcSEcCtD
Cyclophosphamide—Pancytopenia—Doxorubicin—urinary bladder cancer	8e-05	0.00022	CcSEcCtD
Cyclophosphamide—Renal failure—Epirubicin—urinary bladder cancer	7.98e-05	0.000219	CcSEcCtD
Cyclophosphamide—Body temperature increased—Cisplatin—urinary bladder cancer	7.97e-05	0.000219	CcSEcCtD
Cyclophosphamide—Fatigue—Etoposide—urinary bladder cancer	7.96e-05	0.000219	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Epirubicin—urinary bladder cancer	7.95e-05	0.000219	CcSEcCtD
Cyclophosphamide—Stomatitis—Epirubicin—urinary bladder cancer	7.91e-05	0.000217	CcSEcCtD
Cyclophosphamide—Jaundice—Epirubicin—urinary bladder cancer	7.91e-05	0.000217	CcSEcCtD
Cyclophosphamide—Constipation—Etoposide—urinary bladder cancer	7.9e-05	0.000217	CcSEcCtD
Cyclophosphamide—Pain—Etoposide—urinary bladder cancer	7.9e-05	0.000217	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Epirubicin—urinary bladder cancer	7.89e-05	0.000217	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Fluorouracil—urinary bladder cancer	7.83e-05	0.000215	CcSEcCtD
Cyclophosphamide—Haemoglobin—Methotrexate—urinary bladder cancer	7.82e-05	0.000215	CcSEcCtD
Cyclophosphamide—Haemorrhage—Methotrexate—urinary bladder cancer	7.78e-05	0.000214	CcSEcCtD
Cyclophosphamide—Hepatitis—Methotrexate—urinary bladder cancer	7.78e-05	0.000214	CcSEcCtD
Cyclophosphamide—Sweating—Epirubicin—urinary bladder cancer	7.78e-05	0.000214	CcSEcCtD
Cyclophosphamide—Asthenia—Gemcitabine—urinary bladder cancer	7.76e-05	0.000213	CcSEcCtD
Cyclophosphamide—Haematuria—Epirubicin—urinary bladder cancer	7.74e-05	0.000213	CcSEcCtD
Cyclophosphamide—Weight increased—Doxorubicin—urinary bladder cancer	7.66e-05	0.000211	CcSEcCtD
Cyclophosphamide—Pruritus—Gemcitabine—urinary bladder cancer	7.65e-05	0.00021	CcSEcCtD
Cyclophosphamide—Nausea—Thiotepa—urinary bladder cancer	7.64e-05	0.00021	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Etoposide—urinary bladder cancer	7.61e-05	0.000209	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Doxorubicin—urinary bladder cancer	7.6e-05	0.000209	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Epirubicin—urinary bladder cancer	7.57e-05	0.000208	CcSEcCtD
Cyclophosphamide—Pneumonia—Doxorubicin—urinary bladder cancer	7.55e-05	0.000208	CcSEcCtD
Cyclophosphamide—Pruritus—Fluorouracil—urinary bladder cancer	7.52e-05	0.000207	CcSEcCtD
Cyclophosphamide—Visual impairment—Methotrexate—urinary bladder cancer	7.5e-05	0.000206	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	7.44e-05	0.000205	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Cisplatin—urinary bladder cancer	7.43e-05	0.000204	CcSEcCtD
Cyclophosphamide—Bradycardia—Epirubicin—urinary bladder cancer	7.42e-05	0.000204	CcSEcCtD
Cyclophosphamide—Diarrhoea—Gemcitabine—urinary bladder cancer	7.4e-05	0.000203	CcSEcCtD
Cyclophosphamide—Renal failure—Doxorubicin—urinary bladder cancer	7.38e-05	0.000203	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Methotrexate—urinary bladder cancer	7.36e-05	0.000202	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	7.36e-05	0.000202	CcSEcCtD
Cyclophosphamide—Urticaria—Etoposide—urinary bladder cancer	7.34e-05	0.000202	CcSEcCtD
Cyclophosphamide—Haemoglobin—Epirubicin—urinary bladder cancer	7.32e-05	0.000201	CcSEcCtD
Cyclophosphamide—Stomatitis—Doxorubicin—urinary bladder cancer	7.32e-05	0.000201	CcSEcCtD
Cyclophosphamide—Jaundice—Doxorubicin—urinary bladder cancer	7.32e-05	0.000201	CcSEcCtD
Cyclophosphamide—Rhinitis—Epirubicin—urinary bladder cancer	7.3e-05	0.000201	CcSEcCtD
Cyclophosphamide—Body temperature increased—Etoposide—urinary bladder cancer	7.3e-05	0.000201	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Doxorubicin—urinary bladder cancer	7.3e-05	0.000201	CcSEcCtD
Cyclophosphamide—Hepatitis—Epirubicin—urinary bladder cancer	7.29e-05	0.0002	CcSEcCtD
Cyclophosphamide—Haemorrhage—Epirubicin—urinary bladder cancer	7.29e-05	0.0002	CcSEcCtD
Cyclophosphamide—Diarrhoea—Fluorouracil—urinary bladder cancer	7.27e-05	0.0002	CcSEcCtD
Cyclophosphamide—Tinnitus—Methotrexate—urinary bladder cancer	7.26e-05	0.0002	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Epirubicin—urinary bladder cancer	7.25e-05	0.000199	CcSEcCtD
Cyclophosphamide—Asthenia—Cisplatin—urinary bladder cancer	7.23e-05	0.000199	CcSEcCtD
Cyclophosphamide—Sweating—Doxorubicin—urinary bladder cancer	7.2e-05	0.000198	CcSEcCtD
Cyclophosphamide—Haematuria—Doxorubicin—urinary bladder cancer	7.16e-05	0.000197	CcSEcCtD
Cyclophosphamide—Dizziness—Fluorouracil—urinary bladder cancer	7.03e-05	0.000193	CcSEcCtD
Cyclophosphamide—Visual impairment—Epirubicin—urinary bladder cancer	7.02e-05	0.000193	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Doxorubicin—urinary bladder cancer	7.01e-05	0.000193	CcSEcCtD
Cyclophosphamide—Chills—Methotrexate—urinary bladder cancer	6.98e-05	0.000192	CcSEcCtD
Cyclophosphamide—Diarrhoea—Cisplatin—urinary bladder cancer	6.9e-05	0.00019	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Epirubicin—urinary bladder cancer	6.89e-05	0.000189	CcSEcCtD
Cyclophosphamide—Alopecia—Methotrexate—urinary bladder cancer	6.88e-05	0.000189	CcSEcCtD
Cyclophosphamide—Vomiting—Gemcitabine—urinary bladder cancer	6.88e-05	0.000189	CcSEcCtD
Cyclophosphamide—Bradycardia—Doxorubicin—urinary bladder cancer	6.86e-05	0.000189	CcSEcCtD
Cyclophosphamide—Rash—Gemcitabine—urinary bladder cancer	6.82e-05	0.000187	CcSEcCtD
Cyclophosphamide—Dermatitis—Gemcitabine—urinary bladder cancer	6.81e-05	0.000187	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Etoposide—urinary bladder cancer	6.8e-05	0.000187	CcSEcCtD
Cyclophosphamide—Tinnitus—Epirubicin—urinary bladder cancer	6.79e-05	0.000187	CcSEcCtD
Cyclophosphamide—Erythema—Methotrexate—urinary bladder cancer	6.78e-05	0.000186	CcSEcCtD
Cyclophosphamide—Haemoglobin—Doxorubicin—urinary bladder cancer	6.77e-05	0.000186	CcSEcCtD
Cyclophosphamide—Headache—Gemcitabine—urinary bladder cancer	6.77e-05	0.000186	CcSEcCtD
Cyclophosphamide—Flushing—Epirubicin—urinary bladder cancer	6.76e-05	0.000186	CcSEcCtD
Cyclophosphamide—Vomiting—Fluorouracil—urinary bladder cancer	6.76e-05	0.000186	CcSEcCtD
Cyclophosphamide—Rhinitis—Doxorubicin—urinary bladder cancer	6.76e-05	0.000186	CcSEcCtD
Cyclophosphamide—Haemorrhage—Doxorubicin—urinary bladder cancer	6.74e-05	0.000185	CcSEcCtD
Cyclophosphamide—Hepatitis—Doxorubicin—urinary bladder cancer	6.74e-05	0.000185	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Doxorubicin—urinary bladder cancer	6.71e-05	0.000184	CcSEcCtD
Cyclophosphamide—Rash—Fluorouracil—urinary bladder cancer	6.7e-05	0.000184	CcSEcCtD
Cyclophosphamide—Dermatitis—Fluorouracil—urinary bladder cancer	6.7e-05	0.000184	CcSEcCtD
Cyclophosphamide—Headache—Fluorouracil—urinary bladder cancer	6.66e-05	0.000183	CcSEcCtD
Cyclophosphamide—Dysgeusia—Methotrexate—urinary bladder cancer	6.64e-05	0.000182	CcSEcCtD
Cyclophosphamide—Asthenia—Etoposide—urinary bladder cancer	6.62e-05	0.000182	CcSEcCtD
Cyclophosphamide—Chills—Epirubicin—urinary bladder cancer	6.54e-05	0.00018	CcSEcCtD
Cyclophosphamide—Pruritus—Etoposide—urinary bladder cancer	6.53e-05	0.00018	CcSEcCtD
Cyclophosphamide—Arrhythmia—Epirubicin—urinary bladder cancer	6.51e-05	0.000179	CcSEcCtD
Cyclophosphamide—Visual impairment—Doxorubicin—urinary bladder cancer	6.5e-05	0.000179	CcSEcCtD
Cyclophosphamide—Alopecia—Epirubicin—urinary bladder cancer	6.44e-05	0.000177	CcSEcCtD
Cyclophosphamide—Nausea—Gemcitabine—urinary bladder cancer	6.42e-05	0.000177	CcSEcCtD
Cyclophosphamide—Vomiting—Cisplatin—urinary bladder cancer	6.41e-05	0.000176	CcSEcCtD
Cyclophosphamide—Vision blurred—Methotrexate—urinary bladder cancer	6.39e-05	0.000176	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Doxorubicin—urinary bladder cancer	6.37e-05	0.000175	CcSEcCtD
Cyclophosphamide—Rash—Cisplatin—urinary bladder cancer	6.35e-05	0.000175	CcSEcCtD
Cyclophosphamide—Dermatitis—Cisplatin—urinary bladder cancer	6.35e-05	0.000175	CcSEcCtD
Cyclophosphamide—Erythema—Epirubicin—urinary bladder cancer	6.34e-05	0.000174	CcSEcCtD
Cyclophosphamide—Diarrhoea—Etoposide—urinary bladder cancer	6.32e-05	0.000174	CcSEcCtD
Cyclophosphamide—Nausea—Fluorouracil—urinary bladder cancer	6.32e-05	0.000174	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Methotrexate—urinary bladder cancer	6.29e-05	0.000173	CcSEcCtD
Cyclophosphamide—Tinnitus—Doxorubicin—urinary bladder cancer	6.28e-05	0.000173	CcSEcCtD
Cyclophosphamide—Anaemia—Methotrexate—urinary bladder cancer	6.26e-05	0.000172	CcSEcCtD
Cyclophosphamide—Flushing—Doxorubicin—urinary bladder cancer	6.26e-05	0.000172	CcSEcCtD
Cyclophosphamide—Dysgeusia—Epirubicin—urinary bladder cancer	6.21e-05	0.000171	CcSEcCtD
Cyclophosphamide—Malaise—Methotrexate—urinary bladder cancer	6.11e-05	0.000168	CcSEcCtD
Cyclophosphamide—Dizziness—Etoposide—urinary bladder cancer	6.11e-05	0.000168	CcSEcCtD
Cyclophosphamide—Muscle spasms—Epirubicin—urinary bladder cancer	6.1e-05	0.000168	CcSEcCtD
Cyclophosphamide—Leukopenia—Methotrexate—urinary bladder cancer	6.07e-05	0.000167	CcSEcCtD
Cyclophosphamide—Chills—Doxorubicin—urinary bladder cancer	6.05e-05	0.000166	CcSEcCtD
Cyclophosphamide—Arrhythmia—Doxorubicin—urinary bladder cancer	6.02e-05	0.000166	CcSEcCtD
Cyclophosphamide—Nausea—Cisplatin—urinary bladder cancer	5.99e-05	0.000165	CcSEcCtD
Cyclophosphamide—Vision blurred—Epirubicin—urinary bladder cancer	5.98e-05	0.000164	CcSEcCtD
Cyclophosphamide—Alopecia—Doxorubicin—urinary bladder cancer	5.96e-05	0.000164	CcSEcCtD
Cyclophosphamide—Cough—Methotrexate—urinary bladder cancer	5.91e-05	0.000163	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Epirubicin—urinary bladder cancer	5.88e-05	0.000162	CcSEcCtD
Cyclophosphamide—Convulsion—Methotrexate—urinary bladder cancer	5.87e-05	0.000161	CcSEcCtD
Cyclophosphamide—Vomiting—Etoposide—urinary bladder cancer	5.87e-05	0.000161	CcSEcCtD
Cyclophosphamide—Erythema—Doxorubicin—urinary bladder cancer	5.87e-05	0.000161	CcSEcCtD
Cyclophosphamide—Anaemia—Epirubicin—urinary bladder cancer	5.86e-05	0.000161	CcSEcCtD
Cyclophosphamide—Agitation—Epirubicin—urinary bladder cancer	5.83e-05	0.00016	CcSEcCtD
Cyclophosphamide—Rash—Etoposide—urinary bladder cancer	5.82e-05	0.00016	CcSEcCtD
Cyclophosphamide—Dermatitis—Etoposide—urinary bladder cancer	5.82e-05	0.00016	CcSEcCtD
Cyclophosphamide—Headache—Etoposide—urinary bladder cancer	5.78e-05	0.000159	CcSEcCtD
Cyclophosphamide—Myalgia—Methotrexate—urinary bladder cancer	5.77e-05	0.000159	CcSEcCtD
Cyclophosphamide—Arthralgia—Methotrexate—urinary bladder cancer	5.77e-05	0.000159	CcSEcCtD
Cyclophosphamide—Chest pain—Methotrexate—urinary bladder cancer	5.77e-05	0.000159	CcSEcCtD
Cyclophosphamide—Dysgeusia—Doxorubicin—urinary bladder cancer	5.75e-05	0.000158	CcSEcCtD
Cyclophosphamide—Malaise—Epirubicin—urinary bladder cancer	5.72e-05	0.000157	CcSEcCtD
Cyclophosphamide—Discomfort—Methotrexate—urinary bladder cancer	5.7e-05	0.000157	CcSEcCtD
Cyclophosphamide—Leukopenia—Epirubicin—urinary bladder cancer	5.68e-05	0.000156	CcSEcCtD
Cyclophosphamide—Muscle spasms—Doxorubicin—urinary bladder cancer	5.64e-05	0.000155	CcSEcCtD
Cyclophosphamide—Palpitations—Epirubicin—urinary bladder cancer	5.6e-05	0.000154	CcSEcCtD
Cyclophosphamide—Confusional state—Methotrexate—urinary bladder cancer	5.58e-05	0.000153	CcSEcCtD
Cyclophosphamide—Cough—Epirubicin—urinary bladder cancer	5.53e-05	0.000152	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Methotrexate—urinary bladder cancer	5.53e-05	0.000152	CcSEcCtD
Cyclophosphamide—Vision blurred—Doxorubicin—urinary bladder cancer	5.53e-05	0.000152	CcSEcCtD
Cyclophosphamide—Convulsion—Epirubicin—urinary bladder cancer	5.49e-05	0.000151	CcSEcCtD
Cyclophosphamide—Infection—Methotrexate—urinary bladder cancer	5.49e-05	0.000151	CcSEcCtD
Cyclophosphamide—Nausea—Etoposide—urinary bladder cancer	5.48e-05	0.000151	CcSEcCtD
Cyclophosphamide—Hypertension—Epirubicin—urinary bladder cancer	5.48e-05	0.000151	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Doxorubicin—urinary bladder cancer	5.44e-05	0.00015	CcSEcCtD
Cyclophosphamide—Anaemia—Doxorubicin—urinary bladder cancer	5.42e-05	0.000149	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Methotrexate—urinary bladder cancer	5.42e-05	0.000149	CcSEcCtD
Cyclophosphamide—Chest pain—Epirubicin—urinary bladder cancer	5.4e-05	0.000148	CcSEcCtD
Cyclophosphamide—Arthralgia—Epirubicin—urinary bladder cancer	5.4e-05	0.000148	CcSEcCtD
Cyclophosphamide—Myalgia—Epirubicin—urinary bladder cancer	5.4e-05	0.000148	CcSEcCtD
Cyclophosphamide—Agitation—Doxorubicin—urinary bladder cancer	5.39e-05	0.000148	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Methotrexate—urinary bladder cancer	5.35e-05	0.000147	CcSEcCtD
Cyclophosphamide—Discomfort—Epirubicin—urinary bladder cancer	5.33e-05	0.000147	CcSEcCtD
Cyclophosphamide—Malaise—Doxorubicin—urinary bladder cancer	5.29e-05	0.000145	CcSEcCtD
Cyclophosphamide—Anorexia—Methotrexate—urinary bladder cancer	5.27e-05	0.000145	CcSEcCtD
Cyclophosphamide—Leukopenia—Doxorubicin—urinary bladder cancer	5.25e-05	0.000144	CcSEcCtD
Cyclophosphamide—Confusional state—Epirubicin—urinary bladder cancer	5.22e-05	0.000143	CcSEcCtD
Cyclophosphamide—Palpitations—Doxorubicin—urinary bladder cancer	5.19e-05	0.000143	CcSEcCtD
Cyclophosphamide—Oedema—Epirubicin—urinary bladder cancer	5.18e-05	0.000142	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Epirubicin—urinary bladder cancer	5.18e-05	0.000142	CcSEcCtD
Cyclophosphamide—Hypotension—Methotrexate—urinary bladder cancer	5.17e-05	0.000142	CcSEcCtD
Cyclophosphamide—Infection—Epirubicin—urinary bladder cancer	5.14e-05	0.000141	CcSEcCtD
Cyclophosphamide—Cough—Doxorubicin—urinary bladder cancer	5.12e-05	0.000141	CcSEcCtD
Cyclophosphamide—Shock—Epirubicin—urinary bladder cancer	5.09e-05	0.00014	CcSEcCtD
Cyclophosphamide—Convulsion—Doxorubicin—urinary bladder cancer	5.08e-05	0.00014	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Epirubicin—urinary bladder cancer	5.07e-05	0.000139	CcSEcCtD
Cyclophosphamide—Hypertension—Doxorubicin—urinary bladder cancer	5.07e-05	0.000139	CcSEcCtD
Cyclophosphamide—Tachycardia—Epirubicin—urinary bladder cancer	5.05e-05	0.000139	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	5.04e-05	0.000139	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Epirubicin—urinary bladder cancer	5e-05	0.000138	CcSEcCtD
Cyclophosphamide—Chest pain—Doxorubicin—urinary bladder cancer	5e-05	0.000137	CcSEcCtD
Cyclophosphamide—Arthralgia—Doxorubicin—urinary bladder cancer	5e-05	0.000137	CcSEcCtD
Cyclophosphamide—Myalgia—Doxorubicin—urinary bladder cancer	5e-05	0.000137	CcSEcCtD
Cyclophosphamide—Paraesthesia—Methotrexate—urinary bladder cancer	4.97e-05	0.000137	CcSEcCtD
Cyclophosphamide—Discomfort—Doxorubicin—urinary bladder cancer	4.94e-05	0.000136	CcSEcCtD
Cyclophosphamide—Anorexia—Epirubicin—urinary bladder cancer	4.93e-05	0.000136	CcSEcCtD
Cyclophosphamide—Dyspnoea—Methotrexate—urinary bladder cancer	4.93e-05	0.000136	CcSEcCtD
Cyclophosphamide—Hypotension—Epirubicin—urinary bladder cancer	4.84e-05	0.000133	CcSEcCtD
Cyclophosphamide—Confusional state—Doxorubicin—urinary bladder cancer	4.83e-05	0.000133	CcSEcCtD
Cyclophosphamide—Decreased appetite—Methotrexate—urinary bladder cancer	4.81e-05	0.000132	CcSEcCtD
Cyclophosphamide—Oedema—Doxorubicin—urinary bladder cancer	4.79e-05	0.000132	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Doxorubicin—urinary bladder cancer	4.79e-05	0.000132	CcSEcCtD
Cyclophosphamide—Fatigue—Methotrexate—urinary bladder cancer	4.77e-05	0.000131	CcSEcCtD
Cyclophosphamide—Infection—Doxorubicin—urinary bladder cancer	4.76e-05	0.000131	CcSEcCtD
Cyclophosphamide—Pain—Methotrexate—urinary bladder cancer	4.73e-05	0.00013	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	4.72e-05	0.00013	CcSEcCtD
Cyclophosphamide—Shock—Doxorubicin—urinary bladder cancer	4.71e-05	0.00013	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	4.69e-05	0.000129	CcSEcCtD
Cyclophosphamide—Tachycardia—Doxorubicin—urinary bladder cancer	4.67e-05	0.000128	CcSEcCtD
Cyclophosphamide—Paraesthesia—Epirubicin—urinary bladder cancer	4.65e-05	0.000128	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	4.63e-05	0.000127	CcSEcCtD
Cyclophosphamide—Dyspnoea—Epirubicin—urinary bladder cancer	4.61e-05	0.000127	CcSEcCtD
Cyclophosphamide—Anorexia—Doxorubicin—urinary bladder cancer	4.56e-05	0.000126	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Methotrexate—urinary bladder cancer	4.56e-05	0.000125	CcSEcCtD
Cyclophosphamide—Decreased appetite—Epirubicin—urinary bladder cancer	4.5e-05	0.000124	CcSEcCtD
Cyclophosphamide—Hypotension—Doxorubicin—urinary bladder cancer	4.47e-05	0.000123	CcSEcCtD
Cyclophosphamide—Fatigue—Epirubicin—urinary bladder cancer	4.46e-05	0.000123	CcSEcCtD
Cyclophosphamide—Constipation—Epirubicin—urinary bladder cancer	4.43e-05	0.000122	CcSEcCtD
Cyclophosphamide—Pain—Epirubicin—urinary bladder cancer	4.43e-05	0.000122	CcSEcCtD
Cyclophosphamide—Urticaria—Methotrexate—urinary bladder cancer	4.39e-05	0.000121	CcSEcCtD
Cyclophosphamide—Body temperature increased—Methotrexate—urinary bladder cancer	4.37e-05	0.00012	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	4.36e-05	0.00012	CcSEcCtD
Cyclophosphamide—Paraesthesia—Doxorubicin—urinary bladder cancer	4.3e-05	0.000118	CcSEcCtD
Cyclophosphamide—Dyspnoea—Doxorubicin—urinary bladder cancer	4.27e-05	0.000117	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Epirubicin—urinary bladder cancer	4.27e-05	0.000117	CcSEcCtD
Cyclophosphamide—Decreased appetite—Doxorubicin—urinary bladder cancer	4.16e-05	0.000114	CcSEcCtD
Cyclophosphamide—Fatigue—Doxorubicin—urinary bladder cancer	4.13e-05	0.000114	CcSEcCtD
Cyclophosphamide—Urticaria—Epirubicin—urinary bladder cancer	4.11e-05	0.000113	CcSEcCtD
Cyclophosphamide—Pain—Doxorubicin—urinary bladder cancer	4.1e-05	0.000113	CcSEcCtD
Cyclophosphamide—Constipation—Doxorubicin—urinary bladder cancer	4.1e-05	0.000113	CcSEcCtD
Cyclophosphamide—Body temperature increased—Epirubicin—urinary bladder cancer	4.09e-05	0.000112	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Methotrexate—urinary bladder cancer	4.07e-05	0.000112	CcSEcCtD
Cyclophosphamide—Asthenia—Methotrexate—urinary bladder cancer	3.97e-05	0.000109	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Doxorubicin—urinary bladder cancer	3.95e-05	0.000108	CcSEcCtD
Cyclophosphamide—Pruritus—Methotrexate—urinary bladder cancer	3.91e-05	0.000108	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Epirubicin—urinary bladder cancer	3.81e-05	0.000105	CcSEcCtD
Cyclophosphamide—Urticaria—Doxorubicin—urinary bladder cancer	3.8e-05	0.000105	CcSEcCtD
Cyclophosphamide—Body temperature increased—Doxorubicin—urinary bladder cancer	3.79e-05	0.000104	CcSEcCtD
Cyclophosphamide—Diarrhoea—Methotrexate—urinary bladder cancer	3.78e-05	0.000104	CcSEcCtD
Cyclophosphamide—Asthenia—Epirubicin—urinary bladder cancer	3.71e-05	0.000102	CcSEcCtD
Cyclophosphamide—Pruritus—Epirubicin—urinary bladder cancer	3.66e-05	0.000101	CcSEcCtD
Cyclophosphamide—Dizziness—Methotrexate—urinary bladder cancer	3.66e-05	0.000101	CcSEcCtD
Cyclophosphamide—Diarrhoea—Epirubicin—urinary bladder cancer	3.54e-05	9.74e-05	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Doxorubicin—urinary bladder cancer	3.53e-05	9.7e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Methotrexate—urinary bladder cancer	3.52e-05	9.67e-05	CcSEcCtD
Cyclophosphamide—Rash—Methotrexate—urinary bladder cancer	3.49e-05	9.59e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Methotrexate—urinary bladder cancer	3.48e-05	9.58e-05	CcSEcCtD
Cyclophosphamide—Headache—Methotrexate—urinary bladder cancer	3.46e-05	9.53e-05	CcSEcCtD
Cyclophosphamide—Asthenia—Doxorubicin—urinary bladder cancer	3.44e-05	9.45e-05	CcSEcCtD
Cyclophosphamide—Dizziness—Epirubicin—urinary bladder cancer	3.42e-05	9.41e-05	CcSEcCtD
Cyclophosphamide—Pruritus—Doxorubicin—urinary bladder cancer	3.39e-05	9.31e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Epirubicin—urinary bladder cancer	3.29e-05	9.05e-05	CcSEcCtD
Cyclophosphamide—Nausea—Methotrexate—urinary bladder cancer	3.29e-05	9.03e-05	CcSEcCtD
Cyclophosphamide—Diarrhoea—Doxorubicin—urinary bladder cancer	3.28e-05	9.01e-05	CcSEcCtD
Cyclophosphamide—Rash—Epirubicin—urinary bladder cancer	3.26e-05	8.97e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Epirubicin—urinary bladder cancer	3.26e-05	8.96e-05	CcSEcCtD
Cyclophosphamide—Headache—Epirubicin—urinary bladder cancer	3.24e-05	8.91e-05	CcSEcCtD
Cyclophosphamide—Dizziness—Doxorubicin—urinary bladder cancer	3.17e-05	8.71e-05	CcSEcCtD
Cyclophosphamide—Nausea—Epirubicin—urinary bladder cancer	3.07e-05	8.45e-05	CcSEcCtD
Cyclophosphamide—Vomiting—Doxorubicin—urinary bladder cancer	3.04e-05	8.37e-05	CcSEcCtD
Cyclophosphamide—Rash—Doxorubicin—urinary bladder cancer	3.02e-05	8.3e-05	CcSEcCtD
Cyclophosphamide—Dermatitis—Doxorubicin—urinary bladder cancer	3.02e-05	8.29e-05	CcSEcCtD
Cyclophosphamide—Headache—Doxorubicin—urinary bladder cancer	3e-05	8.25e-05	CcSEcCtD
Cyclophosphamide—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	2.98e-05	0.000299	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	2.96e-05	0.000297	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	2.91e-05	0.000291	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—TYMP—urinary bladder cancer	2.9e-05	0.000291	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	2.9e-05	0.00029	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—GSTP1—urinary bladder cancer	2.87e-05	0.000287	CbGpPWpGaD
Cyclophosphamide—Nausea—Doxorubicin—urinary bladder cancer	2.84e-05	7.82e-05	CcSEcCtD
Cyclophosphamide—CYP3A7—Metabolism—ENO2—urinary bladder cancer	2.84e-05	0.000284	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	2.84e-05	0.000284	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—TYMP—urinary bladder cancer	2.83e-05	0.000284	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	2.81e-05	0.000282	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—RRM2—urinary bladder cancer	2.81e-05	0.000281	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	2.75e-05	0.000276	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	2.75e-05	0.000275	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	2.74e-05	0.000275	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	2.74e-05	0.000275	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	2.72e-05	0.000272	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PRSS3—urinary bladder cancer	2.68e-05	0.000268	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—TYMS—urinary bladder cancer	2.67e-05	0.000267	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—NCOR1—urinary bladder cancer	2.64e-05	0.000264	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—GSTM1—urinary bladder cancer	2.64e-05	0.000264	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—NAT2—urinary bladder cancer	2.62e-05	0.000263	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.62e-05	0.000262	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—HPGDS—urinary bladder cancer	2.6e-05	0.00026	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—ENO2—urinary bladder cancer	2.6e-05	0.00026	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	2.59e-05	0.000259	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	2.57e-05	0.000257	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—NAT2—urinary bladder cancer	2.56e-05	0.000257	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.53e-05	0.000254	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.53e-05	0.000253	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—GPX1—urinary bladder cancer	2.52e-05	0.000253	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	2.52e-05	0.000253	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—GSTT1—urinary bladder cancer	2.52e-05	0.000253	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	2.5e-05	0.000251	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—ERCC2—urinary bladder cancer	2.48e-05	0.000248	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.46e-05	0.000247	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—TYMP—urinary bladder cancer	2.46e-05	0.000246	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.41e-05	0.000241	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.36e-05	0.000236	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.34e-05	0.000235	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—MTHFR—urinary bladder cancer	2.33e-05	0.000233	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.29e-05	0.00023	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—NQO1—urinary bladder cancer	2.29e-05	0.000229	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—RRM2—urinary bladder cancer	2.26e-05	0.000227	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—NAT2—urinary bladder cancer	2.22e-05	0.000223	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—RRM2—urinary bladder cancer	2.21e-05	0.000222	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.2e-05	0.00022	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—TYMP—urinary bladder cancer	2.19e-05	0.00022	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.18e-05	0.000218	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.18e-05	0.000218	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—TYMP—urinary bladder cancer	2.14e-05	0.000214	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.11e-05	0.000211	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.1e-05	0.00021	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—ENO2—urinary bladder cancer	2.1e-05	0.00021	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—HPGDS—urinary bladder cancer	2.1e-05	0.00021	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—NQO1—urinary bladder cancer	2.09e-05	0.00021	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.05e-05	0.000206	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—ENO2—urinary bladder cancer	2.05e-05	0.000205	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	2.05e-05	0.000205	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—GSTT1—urinary bladder cancer	2.03e-05	0.000204	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—TYMP—urinary bladder cancer	2.02e-05	0.000202	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2e-05	0.000201	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—TYMP—urinary bladder cancer	2e-05	0.0002	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.99e-05	0.000199	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	1.99e-05	0.000199	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—NAT2—urinary bladder cancer	1.98e-05	0.000199	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.96e-05	0.000196	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.94e-05	0.000194	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.93e-05	0.000194	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.92e-05	0.000192	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—RRM2—urinary bladder cancer	1.92e-05	0.000192	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	1.91e-05	0.000191	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—PPARG—urinary bladder cancer	1.89e-05	0.000189	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—NAT2—urinary bladder cancer	1.82e-05	0.000183	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—CREBBP—urinary bladder cancer	1.81e-05	0.000182	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.81e-05	0.000181	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.79e-05	0.00018	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	1.78e-05	0.000178	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—ENO2—urinary bladder cancer	1.78e-05	0.000178	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—TYMS—urinary bladder cancer	1.77e-05	0.000178	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.76e-05	0.000177	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	1.75e-05	0.000176	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	1.75e-05	0.000176	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—GSTP1—urinary bladder cancer	1.75e-05	0.000175	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.72e-05	0.000173	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	1.72e-05	0.000173	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—RRM2—urinary bladder cancer	1.71e-05	0.000171	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.7e-05	0.00017	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.69e-05	0.00017	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—NQO1—urinary bladder cancer	1.69e-05	0.000169	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—GPX1—urinary bladder cancer	1.68e-05	0.000168	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.67e-05	0.000167	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—NQO1—urinary bladder cancer	1.65e-05	0.000166	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.65e-05	0.000165	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	1.65e-05	0.000165	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—TYMS—urinary bladder cancer	1.62e-05	0.000163	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—NCOR1—urinary bladder cancer	1.61e-05	0.000161	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—GSTM1—urinary bladder cancer	1.61e-05	0.000161	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—ENO2—urinary bladder cancer	1.58e-05	0.000159	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	1.58e-05	0.000159	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.58e-05	0.000158	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.57e-05	0.000158	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.56e-05	0.000156	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	1.55e-05	0.000155	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.55e-05	0.000155	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.55e-05	0.000155	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—GPX1—urinary bladder cancer	1.54e-05	0.000154	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	1.54e-05	0.000154	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.51e-05	0.000152	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	1.51e-05	0.000151	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.5e-05	0.00015	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—PTGS2—urinary bladder cancer	1.49e-05	0.000149	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.46e-05	0.000146	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.46e-05	0.000146	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.44e-05	0.000145	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.44e-05	0.000145	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.44e-05	0.000144	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.43e-05	0.000143	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	1.42e-05	0.000142	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.41e-05	0.000142	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	1.41e-05	0.000141	CbGpPWpGaD
Cyclophosphamide—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.4e-05	0.000141	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.4e-05	0.00014	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.39e-05	0.000139	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.38e-05	0.000138	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	1.38e-05	0.000138	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.32e-05	0.000132	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—TYMS—urinary bladder cancer	1.31e-05	0.000131	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	1.3e-05	0.00013	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	1.3e-05	0.00013	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—PTEN—urinary bladder cancer	1.3e-05	0.00013	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.28e-05	0.000128	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—NQO1—urinary bladder cancer	1.28e-05	0.000128	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	1.27e-05	0.000127	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	1.27e-05	0.000127	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PPARG—urinary bladder cancer	1.26e-05	0.000126	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.25e-05	0.000125	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—GPX1—urinary bladder cancer	1.24e-05	0.000124	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.24e-05	0.000124	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—EP300—urinary bladder cancer	1.24e-05	0.000124	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	1.22e-05	0.000122	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—GPX1—urinary bladder cancer	1.21e-05	0.000122	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.21e-05	0.000121	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	1.21e-05	0.000121	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1.19e-05	0.00012	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.19e-05	0.000119	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.19e-05	0.000119	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.17e-05	0.000118	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.16e-05	0.000117	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.15e-05	0.000116	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PPARG—urinary bladder cancer	1.15e-05	0.000115	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	1.14e-05	0.000115	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.13e-05	0.000113	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.12e-05	0.000112	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.11e-05	0.000111	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	1.11e-05	0.000111	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.1e-05	0.00011	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.1e-05	0.00011	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.08e-05	0.000108	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.07e-05	0.000107	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.05e-05	0.000105	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.04e-05	0.000104	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.03e-05	0.000103	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.03e-05	0.000103	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.03e-05	0.000103	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—TYMS—urinary bladder cancer	9.9e-06	9.93e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	9.88e-06	9.9e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.85e-06	9.88e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	9.8e-06	9.82e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	9.79e-06	9.81e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	9.79e-06	9.81e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	9.71e-06	9.74e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	9.69e-06	9.71e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—TYMS—urinary bladder cancer	9.67e-06	9.69e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—NCOR1—urinary bladder cancer	9.56e-06	9.58e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—GSTM1—urinary bladder cancer	9.56e-06	9.58e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ENO2—urinary bladder cancer	9.53e-06	9.55e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	9.53e-06	9.55e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.4e-06	9.42e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—GPX1—urinary bladder cancer	9.38e-06	9.4e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PPARG—urinary bladder cancer	9.28e-06	9.3e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	9.24e-06	9.26e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	9.2e-06	9.22e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—GPX1—urinary bladder cancer	9.15e-06	9.17e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—TYMS—urinary bladder cancer	9.11e-06	9.13e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PPARG—urinary bladder cancer	9.07e-06	9.09e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	9.05e-06	9.07e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—TYMS—urinary bladder cancer	9.03e-06	9.05e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	9e-06	9.02e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	9e-06	9.02e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—ERCC2—urinary bladder cancer	8.98e-06	9e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	8.93e-06	8.95e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	8.93e-06	8.95e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	8.92e-06	8.94e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	8.72e-06	8.74e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	8.65e-06	8.67e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GPX1—urinary bladder cancer	8.62e-06	8.64e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PTEN—urinary bladder cancer	8.61e-06	8.63e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GPX1—urinary bladder cancer	8.55e-06	8.57e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	8.47e-06	8.48e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—MTHFR—urinary bladder cancer	8.44e-06	8.46e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	8.39e-06	8.41e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—EP300—urinary bladder cancer	8.21e-06	8.23e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	7.96e-06	7.98e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PTEN—urinary bladder cancer	7.89e-06	7.91e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	7.89e-06	7.91e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PPARG—urinary bladder cancer	7.86e-06	7.88e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—NQO1—urinary bladder cancer	7.68e-06	7.7e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	7.55e-06	7.57e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—EP300—urinary bladder cancer	7.53e-06	7.55e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	7.3e-06	7.32e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	7.14e-06	7.15e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PPARG—urinary bladder cancer	7.02e-06	7.03e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PPARG—urinary bladder cancer	6.85e-06	6.86e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	6.74e-06	6.75e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CREBBP—urinary bladder cancer	6.58e-06	6.59e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PPARG—urinary bladder cancer	6.45e-06	6.47e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.41e-06	6.42e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PPARG—urinary bladder cancer	6.4e-06	6.41e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PTEN—urinary bladder cancer	6.37e-06	6.38e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PTEN—urinary bladder cancer	6.23e-06	6.24e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	6.2e-06	6.21e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	6.18e-06	6.2e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	6.15e-06	6.16e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—EP300—urinary bladder cancer	6.07e-06	6.09e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.96e-06	5.97e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—EP300—urinary bladder cancer	5.94e-06	5.95e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.89e-06	5.9e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.89e-06	5.9e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.64e-06	5.65e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.53e-06	5.55e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	5.52e-06	5.53e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PTEN—urinary bladder cancer	5.39e-06	5.4e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PTGS2—urinary bladder cancer	5.39e-06	5.4e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.2e-06	5.21e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—EP300—urinary bladder cancer	5.14e-06	5.15e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	5.08e-06	5.09e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	5.03e-06	5.04e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PTEN—urinary bladder cancer	4.81e-06	4.82e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PTEN—urinary bladder cancer	4.7e-06	4.71e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—EP300—urinary bladder cancer	4.59e-06	4.6e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—EP300—urinary bladder cancer	4.48e-06	4.49e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PTEN—urinary bladder cancer	4.43e-06	4.44e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PTEN—urinary bladder cancer	4.39e-06	4.4e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—EP300—urinary bladder cancer	4.22e-06	4.23e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.22e-06	4.23e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—EP300—urinary bladder cancer	4.19e-06	4.19e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.05e-06	4.06e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.32e-06	3.33e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.89e-06	2.9e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.76e-06	2.77e-05	CbGpPWpGaD
